Table 1.
| |
Total patients | 43 |
Age (yr), mean SD | 65.39 9.1 |
Sex | Female 60% (n = 26) |
Male 40% (n = 17) | |
Reason for aminobisphosphonates use | Osteoporosis 56% (n = 24) |
Metastasis 21% (n = 9) | |
Type of aminobisphosphonates | Zoledronate 67% (n = 29) |
Alendronate 14% (n = 6) | |
Pamidronate 12% (n = 5) | |
Risedronate 7% (n = 3) | |
SD, standard deviation |